George Mulligan, PhD, serves as Chief Scientific Officer at the MMRF. In this role, Dr. Mulligan leads the development, execution, and communication of the MMRF’s overall research strategy to drive clinically meaningful scientific advances for myeloma patients. Dr. Mulligan also contributes to all aspects of the MMRF and its subsidiary companies, the Multiple Myeloma Research Consortium (MMRC) and the Myeloma Investment Fund (MIF), to accelerate the development of next-generation therapies, drive research to deliver more precise and personalized treatment approaches, and empower patients with information and resources to extend their lives.
Dr. Mulligan brings to the MMRF more than 20 years of diverse experience in drug development and translational and clinical research across the biotech and pharmaceutical industry, including extensive research in myeloma. His previous roles include serving as the Chief Scientific Officer at Mitobridge, where he drove the overall scientific and translational strategy for its mitochondrial platform and clinical compounds. Dr. Mulligan was also Senior Director of Translational Medicine at Millennium/Takeda, leading much of its biomarker and translational research strategy for the myeloma treatment Velcade® (bortezomib), and driving early genomics research that helped initiate pivotal initiatives such as the MMRF’s CoMMpass Study—the most comprehensive longitudinal genomic study ever conducted in myeloma.